Drug Trial Radar · NCT04167553
Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities
Last checked: Nov 19, 2026Latest source record: Jan 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
52
Actual
Start
Aug 30, 2019
Primary completion
Dec 9, 2020
Study completion Dec 9, 2020
Sponsor
- Lead sponsor
- Hanmi Pharmaceutical Company LimitedIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2019
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The planned period of each cohort is 22 weeks including subject screening, treatments for 12 weeks, and follow up period.
Conditions
- Obese With Comorbidities
- Overweight With Comorbidities
- Type2 Diabetes
Interventions
HM15136Drug
In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional. In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.
PlaceboDrug
In Part 1, approximately 36 subjects, divided into 3 cohorts with 12 subjects (HM15136 group 9 subjects, placebo group 3 subjects) per cohort. In Part 2, approximately 66 subjects, in up to 4 cohort with 30 subjects for cohort 4 (HM15136 group 15 subjects, placebo group 15 subjects) and 12 subjects per cohorts 5-7 (HM15136 group 9 subjects, placebo group 3 subjects). Cohorts 6 and 7 are optional. In the end of study, Part 2 of the study consisted of 2 cohorts comprising 16 subjects total.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To Evaluate the Incidence of AEsTime frame: after multiple subcutaneous (SC) doses for 12 weeks
- To Evaluate Serum Amylase Levels at 12 WeeksTime frame: after multiple subcutaneous (SC) doses for 12 weeks
- Change From Baseline in Tympanic TemperatureTime frame: after multiple subcutaneous (SC) doses for 12 weeks
- Change From Baseline in 12-lead ECG ParametersTime frame: after multiple subcutaneous (SC) doses for 12 weeks
- Injection Site ReactionsTime frame: after multiple subcutaneous (SC) doses for 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Prosciento
San Diego, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.